(Q45855167)

17 December 2017

title

Inhibitor development and substitution therapy in a developing country: Turkey (English)

1 reference

17 December 2017

author name string

Kavakli K

1

1 reference

17 December 2017

Gringeri A

2

1 reference

17 December 2017

Bader R

3

1 reference

17 December 2017

Nisli G

4

1 reference

17 December 2017

Polat A

5

1 reference

17 December 2017

Aydinok Y

6

1 reference

17 December 2017

publication date

1 March 1998

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

4

1 reference

17 December 2017

issue

2

1 reference

17 December 2017

page(s)

104-108

1 reference

17 December 2017

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.00171.X

Hemophilia 1996. New approach to an old disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.00171.X

Inhibitors in hemophilia patients: current status and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.00171.X

Inhibitors of factor VIII and IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.00171.X

Inhibitors in congenital haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.00171.X

Epidemiology of inhibitors in haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.00171.X

Prophylactic therapy for hemophilia in a developing country, Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.00171.X

Why do so many haemophilia A patients develop an inhibitor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.00171.X

Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.00171.X

Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.00171.X

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.1998.00171.X

10.1046/J.1365-2516.1998.00171.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

release_gqvubc5nergi5nvlsvdylbivni

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gqvubc5nergi5nvlsvdylbivni

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

17 December 2017